AG
GNMX

Advisor Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Advisor Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-525
Closed -$1K – 5129
2018
Q1 		$1K Hold
525
– – ﹤0.01% 4895
2017
Q4 		$1K Hold
525
– – ﹤0.01% 4902
2017
Q3 		$1K Hold
525
– – ﹤0.01% 4772
2017
Q2 		$1K Hold
525
– – ﹤0.01% 4728
2017
Q1 		$1K Hold
525
– – ﹤0.01% 4625
2016
Q4 		$3K Hold
525
– – ﹤0.01% 4163
2016
Q3 		$3K Buy
+525
New +$2.99K ﹤0.01% 4110

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Advisor Group's GNMX Position: Q2 2018 in Review

Advisor Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2018, closing a stake of 525 shares — an estimated $1K sold.

Advisor Group first reported a position in GNMX in Q3 2016 and held it in 7 quarters. The position peaked at $3K in Q4 2016. 40 funds tracked by Wall St. Rank hold GNMX as of Q2 2018.

  • Advisor Group reported no remaining Aevi Genomic Medicine Inc position as of Q2 2018 after selling out during the quarter.
  • Advisor Group sold 525 Aevi Genomic Medicine Inc shares in Q2 2018, an estimated $1K.
  • Advisor Group first reported a position in Aevi Genomic Medicine Inc in Q3 2016 and held it in 7 quarters.
  • Advisor Group's Aevi Genomic Medicine Inc position peaked at $3K in Q4 2016.
  • 40 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2018.

Based on Advisor Group's 13F filing for Q2 2018, filed 13 Aug 2018.